Top Markets
#1 MowCat MowCat +48.88%
#2 Audiera Audiera +27.37%
#3 Bermuda Shorts Bermuda Shorts +25.32%
#4 Velvet Velvet +23.57%
#5 aPriori aPriori +20.94%
#6 Quack AI Quack AI +19.92%
#7 Derive Derive +19.06%
#8 Biconomy Biconomy +18.82%
#9 SkyAI SkyAI +13.80%
#10 Geodnet Geodnet +11.33%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc.

AZRX
Rank in Stocks #35193
AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12... AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).
Share Price
$3.45
Last synced: 2021-09-21
Market Cap
$4.29M
Change (1 day)
2.07%
Change (1 year)
0.00%
Country
US
Trade AzurRx BioPharma, Inc. (AZRX)

Category

Healthcare
Revenue for AzurRx BioPharma, Inc. (AZRX)
Revenue in Aug 2026 TTM: 0
According to AzurRx BioPharma, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AzurRx BioPharma, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE